October 14th 2024
Drs Gerds and McCloskey discuss JAK inhibitors for patients with myelofibrosis, tips for symptom management, and emerging myelofibrosis research.
August 6th 2024
Aaron Gerds, MD, discusses clinical implications and areas of unmet need for patients with low- or intermediate-1–risk myelofibrosis.
July 10th 2024
Aaron Gerds, MD, discusses disease progression patterns from the MOST trial in patients with low-risk myelofibrosis.
June 14th 2024
Aaron Gerds, MD, discusses the clinical implications of outcomes with pelabresib plus ruxolitinib therapy in JAK inhibitor–naive myelofibrosis.
May 31st 2024
Aaron Gerds, MD, discusses updated efficacy and safety results for pelabresib and ruxolitinib in JAK inhibitor–naive myelofibrosis.
January 4th 2024
Aaron Gerds, MD, discusses the importance of evaluating the efficacy and safety of selinexor in patients with JAK inhibitor–naive myelofibrosis, as assessed in the phase 1/3 XPORT-MF-034 trial.
April 26th 2023
Shared closing thoughts on the future treatment landscape for myeloproliferative neoplasms, including future and emerging areas of research and remaining areas of unmet need.
A review of recent trial data evaluating combination therapy approaches with ruxolitinib in myelofibrosis, including the rationale and potential clinical benefits associated with the use of these emerging strategies.
April 19th 2023
Focused discussion on emerging trial data surrounding novel, investigational therapies for myelofibrosis.
Expert perspectives on treatment sequencing strategies with JAK inhibitors for myelofibrosis.
April 12th 2023
Shared insights on monitoring strategies for myelofibrosis, including important considerations for patients receiving treatment with JAK inhibitors.
Panel experts briefly review supporting data for the use of JAK inhibitors in myelofibrosis and discuss the impact of emerging data on the current treatment landscape.
April 5th 2023
Expert perspectives on how to identify and assess patients with myelofibrosis for transplant therapy.
Comprehensive discussion highlighting diagnostic and molecular testing involved in the diagnosis of myelofibrosis, challenges related to early diagnosis, and consideration factors for assessing prognostic risk.
March 29th 2023
Shared insight on classification, risk factors, and important biomarkers and pathways in myelofibrosis.
Panel experts share insight regarding prognosis for patients with polycythemia vera and the associated risk for progression to myelofibrosis.
March 22nd 2023
A review of systemic treatment options used in polycythemia vera and the roles these play in the current treatment landscape.
A brief overview of myeloproliferative neoplasms and the associated signs and symptoms commonly presenting in patients.
January 6th 2023
Dr Aaron Gerds provides insights and reviews updated data from the MOMENTUM study that evaluated the use of momelotinib in patients with myelofibrosis who previously received a JAK inhibitor.
January 3rd 2023
Dr Aaron Gerds discusses the long term safety data of momelotinib, a JAK1/JAK2 inhibitor, in patients with myelofibrosis.